Cfmp Improve The Clinical Observation Of Patients With Refractory Acute Leukemia Survival

Refractory acute leukemia is characterized by poor reaction to chemotherapy,low alleviation rate to induction,and high mortality rate. Currently,rotating different chemotherapy regimens and increasing the dose of chemotherapy drugs are the main methods to treat refractory leukemia, but there is only 30%-45% of clinical remission rate.In addition, problems such as short sustained remission time,easy to relapse,and short survival time still exist in terms of refractory leukemia. Therefore,while improving the remission rate for patients with refractory leukemia, lengthening its sustained remissiontime and reducing its death rate is also of great significance. This clinical study is part of the project "Clinical Applied Research on TCM TherapeuticSchedule for Refractory Acute Leukemia in Perichemotherapy Period" which is backed up by the "the Eleventh Five-year" national science supporting project (project NO.2006BAI04A18).Objective:To observe the effects of Compound Granule Prescription of Thunberg Fritillary Bulb as the main intervention and treatment protocol on sustained remission time,median survival time, the relapse rate,and mortality rate on refractory acute leukemia patients.Method:According to the requirements of the "National Support Scheme" and GCP, using randomized double-blind, placebo-controlled and multi-center clinical research as principles, we combine Chinese interventions with standard chemotherapy of western medicine on treating 238 patients with refractory acute leukemia before and after chemotherapy and carry out follow-up to subjects who has been completely alleviated after one standard chemotherapy course to get knowledge of sustained remission time,survival time, the relapse rate and morbidity.41 patients were finally accounted into the statistic with 20 from treatment group and 21 from controlled group.Results:Comparison with the control group:The sustained remission time for the treatment group and the control group is 172 days and 115days respectively; median survival time is 363 days and 201 days without significant difference (P>0.05). But the treatment grouphas more advantage in sustained remission time and survival time. The relapse rate of the treatment group within 3 months,6 months,1 year and the totalrelapse rate are 30%,50%,70% and 90% respectively,which is 42%,76%,90.48%,90.48% lower than that of the controlled group, without statistically significance (P>0.05). The treatment group has a decline trend in relapse rate. Themortality rate of the treatment group is 80%,5.7% lower than 85.71 of the controlled group. Both groups have no statistically significance(P>0.05).But the treatment group has a decline trend in mortality rate.Comparison with foreign literature:On reviewing recent foreign literature, we found that the treatment group has a certain advantage in terms of the sustained remission time and median survival time.Conclusion:Compound Granule Prescription of Thunberg Fritillary Bulb can lengthen the sustained remission time for refractory acute leukemia patients and increase their survival time and reduce relapse rate and mortality rate.